[Asia Economy Reporter Park Jun-yi] HLB Life Science announced on the 8th that it has received approval from the Ministry of Food and Drug Safety for the Phase 1 clinical trial plan of the LSD1 inhibitor (SP-2577) for the treatment of recurrent and refractory Ewing sarcoma patients.
HLB Life Science stated, "We will determine the maximum tolerated dose of SP-2577 in patients with recurrent or refractory Ewing sarcoma and evaluate its safety, tolerability, pharmacokinetic properties, and antitumor activity."
They also explained, "Through the Phase 1 clinical trial, we expect to gain a competitive advantage in developing targeted therapies for the rare disease Ewing sarcoma."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
